Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

MrTicker Sep. 10 at 12:31 PM

$QNRX Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICUThis New Video Explores the Daily Realities of Raising a Child with Netherton Syndrome, and Its Impact on the Whole Family GLOBENEWSWIRE 7:30 AM ET 9/10/2026

0 · Reply

MrTicker Sep. 8 at 6:13 PM

$QNRX CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome GLOBENEWSWIRE 1:12 PM ET 9/8/2026

0 · Reply

prismmarketview Sep. 8 at 3:26 PM

Most FDA designations can help a drug move through development. Rare Pediatric Disease Designation carries something else: the potential for a tradable Priority Review Voucher upon drug approval. Quoin Pharmaceuticals $QNRX now holds two RPD designations for investigational QRX003, after the FDA granted its second in Peeling Skin Syndrome, a rare disease with no approved treatment. @QuoinPharma https://prismmarketview.com/one-asset-two-rare-pediatric-disease-designations-quoins-regulatory-build/

0 · Reply

MrPlastic Sep. 8 at 12:53 PM

$QNRX and the optionality the ~zero EV ignores just got bigger: FDA granted a SECOND Rare Pediatric Disease Designation (PSS, on top of Netherton) — two potential PRVs, which per mgmt could be >$300M in non-dilutive cash if approved. That's 7x the current market cap in vouchers alone, separate from any drug revenue. Still contingent on approval — but it's all priced at zero right now.

0 · Reply

MrTicker Sep. 8 at 12:31 PM

$QNRX Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome GLOBENEWSWIRE 7:30 AM ET 9/8/2026

0 · Reply

Stock_Catcher Sep. 8 at 12:31 PM

$QNRX Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

0 · Reply

JFais Sep. 4 at 4:39 PM

Chat Rundown for Friday: $RARE - interesting to see rationale behind multiple new entries & options trades $ABVX longs convinced lows ripe for adds $QNRX phase 2/3 data Q2 2027, but skepticism on market potential for genoderms. Topical rapamycin platform moving forward $PVLA

0 · Reply

ajmrtxl Sep. 4 at 12:16 PM

$QNRX 's latest squeeze play

0 · Reply

Tradingistheway Sep. 3 at 7:50 PM

$QNRX $100??

1 · Reply

goalseeker Sep. 3 at 7:42 PM

$PURR $QNRX heads up ⬆️ 🤔

0 · Reply

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

Sep 8, 2026, 2:12 PM EDT - 4 days ago

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

2026-09-08T13:05:27.000Z - 5 days ago

Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003

Sep 8, 2026, 8:30 AM EDT - 5 days ago

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

2026-08-28T10:10:34.000Z - 16 days ago

Quoin Pharmaceuticals announces $50M private placement

2026-08-28T10:05:21.000Z - 16 days ago

Quoin Pharmaceuticals reports ‘positive’ data from Phase 2/3 study of QRX003

Aug 28, 2026, 6:00 AM EDT - 16 days ago

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

Aug 28, 2026, 6:00 AM EDT - 16 days ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

2026-08-16T13:18:53.000Z - 4 weeks ago

Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)

Aug 14, 2026, 9:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Earnings release: Q2 2026

Aug 14, 2026, 9:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Quarterly report: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 7, 2026, 8:30 AM EDT - 5 weeks ago

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

Jul 16, 2026, 8:00 AM EDT - 1 month ago

Quoin Pharmaceuticals Proxy statement: Proxy filing

2026-07-09T13:16:10.000Z - 2 months ago

Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application

Jul 9, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Jul 6, 2026, 8:00 AM EDT - 2 months ago

Quoin Pharmaceuticals Proxy statement: Proxy filing

2026-06-30T13:00:12.000Z - 2 months ago

Quoin Pharmaceuticals receives notice of allowance for QRX003 patent

Jun 30, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

2026-06-23T15:37:03.000Z - 2 months ago

Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

2026-06-18T12:49:30.000Z - 2 months ago

Quoin Pharmaceuticals completes establishment of subsidiary in Japan

Jun 18, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

2026-06-16T13:18:35.000Z - 2 months ago

Quoin reports positive pediatric data in Netherton Syndrome program

Jun 16, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

2026-06-15T10:17:58.000Z - 3 months ago

Quoin Pharmaceuticals initiated with a Buy at ThinkEquity

2026-06-04T12:45:47.000Z - 3 months ago

Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan

Jun 4, 2026, 8:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

2026-06-02T14:36:20.000Z - 3 months ago

Quoin Pharmaceuticals submits QRX003 IND application to FDA

Jun 2, 2026, 8:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

May 7, 2026, 9:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 9:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

2026-05-04T10:11:14.000Z - 4 months ago

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 28, 2026, 12:02 PM EDT - 4 months ago

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

2026-04-28T13:41:57.000Z - 4 months ago

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

2026-03-27T11:06:44.000Z - 5 months ago

Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global

Mar 26, 2026, 9:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Earnings release: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Annual report: Q4 2025

2026-03-25T13:40:52.000Z - 5 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-03-25T13:35:56.000Z - 5 months ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

2026-03-25T12:55:48.000Z - 5 months ago

Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Quoin Pharmaceuticals Slides: Corporate presentation

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

2026-03-11T12:38:45.000Z - 6 months ago

Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

Mar 11, 2026, 8:30 AM EDT - 6 months ago

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

2026-02-26T13:53:53.000Z - 6 months ago

Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program

Jan 27, 2026, 8:30 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Jan 20, 2026, 8:30 AM EST - 7 months ago

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Nov 7, 2025, 7:00 AM EST - 10 months ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Nov 6, 2025, 9:30 AM EST - 10 months ago

Quoin Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 10 months ago

Quoin Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 10, 2025, 9:24 AM EDT - 11 months ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Product Portfolio Update

Jul 17, 2025, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jun 13, 2025, 4:27 PM EDT - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation

May 20, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q1 2025

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 1 year ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 1 year ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation

Dec 11, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Earnings release: Q3 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Sep 9, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

MrTicker Sep. 10 at 12:31 PM

0 · Reply

MrTicker Sep. 8 at 6:13 PM

$QNRX CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome GLOBENEWSWIRE 1:12 PM ET 9/8/2026

0 · Reply

prismmarketview Sep. 8 at 3:26 PM

0 · Reply

MrPlastic Sep. 8 at 12:53 PM

0 · Reply

MrTicker Sep. 8 at 12:31 PM

$QNRX Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome GLOBENEWSWIRE 7:30 AM ET 9/8/2026

0 · Reply

Stock_Catcher Sep. 8 at 12:31 PM

$QNRX Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

0 · Reply

JFais Sep. 4 at 4:39 PM

0 · Reply

ajmrtxl Sep. 4 at 12:16 PM

$QNRX 's latest squeeze play

0 · Reply

Tradingistheway Sep. 3 at 7:50 PM

$QNRX $100??

1 · Reply

goalseeker Sep. 3 at 7:42 PM

$PURR $QNRX heads up ⬆️ 🤔

0 · Reply

goalseeker Sep. 3 at 7:16 PM

$QNRX 🧨 🧨 cooking to $50:00!!

0 · Reply

carefour Sep. 3 at 7:16 PM

$QNRX in

0 · Reply

Tradingistheway Sep. 3 at 7:12 PM

$QNRX $9???

0 · Reply

Tradingistheway Sep. 3 at 3:30 PM

$QNRX $10????

0 · Reply

goalseeker Sep. 3 at 3:23 PM

$QNRX been sitting on this for a while but looks like pay 💰 dirt soon 🔜 $$$

0 · Reply

CEOBuysDisclosures Sep. 2 at 3:45 AM

$QNRX CEO purchased 20,490 shares at $4.88 for a total of $99,991. Myers Michael now owns 37,713 shares. https://ceo-buys.com

0 · Reply

AlertsAndNews Sep. 2 at 2:49 AM

$QNRX Quoin Pharmaceuticals Form 4s, Multiple Insider Buys Michael Myers (Director & CEO) Buys 30,735 @ $3.25 Denise P. Carter (Director & COO) Buys 30,735 @ $3.25 Sally Bridget Lawlor (CFO) Buys 15,366 @ $3.25 Anthony James Culverwell (Director) Buys 9,219 @ $3.25 "Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88."

1 · Reply

WhoDoneIt69 Sep. 1 at 8:44 PM

$QNRX This company is a legitimate scam, they survive off diluting their investors. Anyone playing the action.. good luck, for those thinking you’ll hold and average down, selling now is the only way to mitigate loss, you don’t want to be long here, your value will eventually go to ZERO. Take it from the guy who held on for 4 years of reverse splits to regain compliance followed by dilution via offerings.. I never sold and somehow no longer own a single share. Take heed.

0 · Reply

Tradingistheway Sep. 1 at 2:22 PM

$QNRX $15?

0 · Reply

onkelhubert Sep. 1 at 8:59 AM

$QNRX IB today shows borrow rate of 341% with 73k shares to borrow.

0 · Reply

JMJTrading Aug. 31 at 7:10 PM

$NCPL Look at my previous calls, I have hit ever one $USDE called Friday at $6.65, this week it is $NCPL $GNS $PASW $QNRX

1 · Reply

Market Cap	13.64M
Revenue (ttm)	0.00
Net Income (ttm)	-15.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	65,600
Avg Vol	681,098
Day's Range	N/A - N/A
Shares Out	2.01M
Stochastic %K	53%
Beta	1.51
Analysts	Strong Sell
Price Target	$19.25